Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel. In this important role, Sarah will be responsible for directing and managing all of the company’s legal activities. She will report directly to the company’s CEO. Sarah rejoins Psychemedics from ... Read more

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek had joined the Company as Vice President, Controller. In this important role, Andrew will be responsible for directing and managing all of the Company’s financial activities, including external reporting and internal analysis. He will report directly to the Company’s ... Read more

Robyn C. Davis Joins Psychemedics Board of Directors

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long-time and dedicated Psychemedics ... Read more

Psychemedics Announces a “Vaping Panel” to Detect and Deter the use of Marijuana, CBD and Nicotine

A New and Cost-Effective Tool to Combat the E-cigarette Epidemic Among Youth ACTON, MA, May 5, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced a Vaping Panel to detect the use of Marijuana, CBD and Nicotine. This test provides a … Read more

Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA

A New and Cost-Effective Tool to Detect and Deter Nicotine use ACTON, MA, April 29, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine. This test provides a way … Read more

Psychemedics Test for Fentanyl Detection Cleared by FDA

Industry’s first and only FDA-cleared Fentanyl screen available now ACTON, MA, April 24, 2019 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ:PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the industry’s first and only FDA-cleared hair test for Fentanyl, a major killer increasingly found in illegal drugs. According to … Read more

Psychemedics Announces First Quarter Results And Declares 91st Consecutive Quarterly Dividend

Acton, MA, April 23, 2019 — Psychemedics Corporation (NASDAQ:PMD) today announced first-quarter financial results for the period ended March 31, 2019. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of May 7, 2019, to be paid on May 17, 2019. This will be the Company’s 91st … Read more

New Psychemedics Offering Further Enhances Cocaine Detection

Industry’s first commercial application of hydroxycocaines for detection SAN ANTONIO, TX and ACTON, MA, March 27, 2019 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader in detecting drugs of abuse using hair analysis, today at the National Drug and Alcohol Screening Association (NDASA) Conference introduced the industry’s first confirmation process to accurately measure … Read more

Psychemedics Announces Addition of FDA-Cleared Benzodiazepines Hair Test

In another first, the world’s largest hair drug testing company & scientific leader launches new test for Benzodiazepines Acton, Massachusetts, September 26, 2017 – Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global leader for over thirty years, announced the launch of its FDA-Cleared Benzodiazepines hair test.  The test detects numerous Benzodiazepines, including Xanax®, Valium®, and … Read more

Psychemedics Corporation Launches Synthetic Cannabinoids Hair Test

World’s largest hair drug testing company & scientific leader launches new tool for combatting rising Synthetic Cannabinoids (K2, Spice) abuse Acton, Massachusetts, August 22, 2017– Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global scientific leader for over thirty years, announced the launch of its Synthetic Cannabinoids test – a hair test that looks for the … Read more